Neema Mafi, MD
Infectious Disease · Phoenix, AZNPI 1558679142
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $815 of the $995 with a category attached, or 81.9%. 7 manufacturers reported payments, led by Merck at 22.6% of the total.
Across 14 payments — averaging $71.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$225
- Astellas Pharma US Inc$180
- Gilead$156
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$141
- Paratek Pharmaceuticals, Inc.$138
- Amgen$134
- plus $21 from 1 others
What the payments were for
- Food & beverage$81582%
- Education$18018%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $225 |
| Astellas Pharma US Inc | 3 | $180 |
| Gilead | 3 | $156 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $141 |
| Paratek Pharmaceuticals, Inc. | 2 | $138 |
| Amgen | 1 | $134 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$995 in reported general payments places this provider in the 75th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 61 | $17,723 |
| ErtapenemErtapenem Sodium | 25 | $10,431 |
| Cefepime Hcl | 39 | $6,292 |
| Vancomycin Hcl | 40 | $5,182 |
| Cefazolin Sodium | 29 | $1,659 |
| Linezolid | 14 | $1,122 |
| CeftriaxoneCeftriaxone Sodium | 47 | $1,113 |
| CefuroximeCefuroxime Axetil | 29 | $719 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 39 | $375 |
| Doxycycline Monohydrate | 15 | $192 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $152 |
| Metronidazole | 14 | $146 |
| Cefadroxil | 17 | $137 |
| Ciprofloxacin Hcl | 18 | $82 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Phoenix
- Thanes VanigPhoenix$258K
- Vipul GanatraPhoenix$151K
- Ana MoranPhoenix$35K
- Robert OrensteinPhoenix$26K
- Adriana GaidiciPhoenix$20K
- Dwight ClarkePhoenix$18K
- Ndidiamaka ObiesiePhoenix$12K
- Ngozi OsonduPhoenix$5K
- Mirella MircescuPhoenix$4K
- Rebekah SensenigPhoenix$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.